Acute myeloid leukemia: the good, the bad, and the ugly

A Kuykendall, N Duployez, N Boissel… - American Society of …, 2018‏ - ascopubs.org
Acute myeloid leukemia (AML) was initially subdivided according to morphology (the French-
American-British system), which proved helpful in pathologic categorization. Subsequently …

METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation

EA Orellana, Q Liu, E Yankova, M Pirouz… - Molecular cell, 2021‏ - cell.com
The emerging" epitranscriptomics" field is providing insights into the biological and
pathological roles of different RNA modifications. The RNA methyltransferase METTL1 …

AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms

K Rejeski, J Duque-Afonso, M Lübbert - Oncogene, 2021‏ - nature.com
Abstract The chromosomal translocation t (8; 21) and the resulting oncofusion gene
AML1/ETO have long served as a prototypical genetic lesion to model and understand …

Targeting an RNA-binding protein network in acute myeloid leukemia

E Wang, SX Lu, A Pastore, X Chen, J Imig, SCW Lee… - Cancer cell, 2019‏ - cell.com
RNA-binding proteins (RBPs) are essential modulators of transcription and translation
frequently dysregulated in cancer. We systematically interrogated RBP dependencies in …

The genomic landscape of core-binding factor acute myeloid leukemias

ZJ Faber, X Chen, AL Gedman, K Boggs, J Cheng… - Nature …, 2016‏ - nature.com
Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently
defined by recurrent cytogenetic abnormalities, including rearrangements involving the core …

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes

G Ehx, JD Larouche, C Durette, JP Laverdure… - Immunity, 2021‏ - cell.com
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly
because of the lack of actionable immune targets. Using an original proteogenomic …

Genomic landscape and clonal evolution of acute myeloid leukemia with t (8; 21): an international study on 331 patients

F Christen, K Hoyer, K Yoshida, HA Hou… - Blood, The Journal …, 2019‏ - ashpublications.org
Acute myeloid leukemia with t (8; 21)(q22; q22) is characterized by considerable clinical and
biological heterogeneity leading to relapse in up to 40% of patients. We sequenced coding …

[HTML][HTML] Immunotherapeutic targeting of surfaceome heterogeneity in AML

ME Bordeleau, É Audemard, A Métois, L Theret, V Lisi… - Cell reports, 2024‏ - cell.com
Immunotherapy remains underexploited in acute myeloid leukemia (AML) compared to other
hematological malignancies. Currently, gemtuzumab ozogamicin is the only therapeutic …

The clinical mutatome of core binding factor leukemia

S Opatz, SA Bamopoulos, KH Metzeler, T Herold… - Leukemia, 2020‏ - nature.com
The fusion genes CBFB/MYH11 and RUNX1/RUNX1T1 block differentiation through
disruption of the core binding factor (CBF) complex and are found in 10–15% of adult de …

Scalable prediction of acute myeloid leukemia using high-dimensional machine learning and blood transcriptomics

S Warnat-Herresthal, K Perrakis, B Taschler, M Becker… - Iscience, 2020‏ - cell.com
Acute myeloid leukemia (AML) is a severe, mostly fatal hematopoietic malignancy. We were
interested in whether transcriptomic-based machine learning could predict AML status …